Crossmark

Migratory and anti-fibrotic programmes define the regenerative potential of human cardiac progenitors

Crossref DOI link: https://doi.org/10.1038/s41556-022-00899-8

Published Online: 2022-05-12

Published Print: 2022-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Poch, Christine M. https://orcid.org/0000-0001-8492-2982
Foo, Kylie S.

De Angelis, Maria Teresa

Jennbacken, Karin https://orcid.org/0000-0003-1254-5158
Santamaria, Gianluca

Bähr, Andrea

Wang, Qing-Dong https://orcid.org/0000-0001-9570-4411
Reiter, Franziska

Hornaschewitz, Nadja

Zawada, Dorota

Bozoglu, Tarik

My, Ilaria

Meier, Anna https://orcid.org/0000-0001-6307-3248
Dorn, Tatjana

Hege, Simon

Lehtinen, Miia L.

Tsoi, Yat Long https://orcid.org/0000-0002-8890-3989
Hovdal, Daniel https://orcid.org/0000-0002-8861-4650
Hyllner, Johan

Schwarz, Sascha

Sudhop, Stefanie

Jurisch, Victoria

Sini, Marcella

Fellows, Mick D.

Cummings, Matthew

Clarke, Jonathan

Baptista, Ricardo

Eroglu, Elif https://orcid.org/0000-0003-3952-3178
Wolf, Eckhard https://orcid.org/0000-0002-0430-9510
Klymiuk, Nikolai

Lu, Kun

Tomasi, Roland

Dendorfer, Andreas https://orcid.org/0000-0002-7806-312X
Gaspari, Marco https://orcid.org/0000-0002-5411-8800
Parrotta, Elvira

Cuda, Giovanni https://orcid.org/0000-0001-6313-1866
Krane, Markus

Sinnecker, Daniel https://orcid.org/0000-0002-8116-9750
Hoppmann, Petra

Kupatt, Christian https://orcid.org/0000-0002-3611-1218
Fritsche-Danielson, Regina https://orcid.org/0000-0003-0582-6429
Moretti, Alessandra https://orcid.org/0000-0001-5782-7832
Chien, Kenneth R. https://orcid.org/0000-0002-2759-8378
Laugwitz, Karl-Ludwig https://orcid.org/0000-0003-4948-4846
License Information

Text and Data Mining valid from 2022-05-01

Version of Record valid from 2022-05-12
More Information

Article History

Received: 12 August 2021

Accepted: 11 March 2022

First Online: 12 May 2022

Competing interests

: J.C. and R.B. are employees of Procella Therapeutics. K.J., Q.-D.W., R.F.-D., J.H., D.H., M.F. and M.S. are employees of AstraZeneca. K.S.F. and K.R.C. are co-inventors on a patent (Patent no. 10508263) based on the HVP technology and its applications. The HVP intellectual property is assigned to Procella Therapeutics. A.D. holds a patent (Patent no. USN 15/781,454) on the technology of biomimetic cultivation and is co-founder and shareholder of InVitroSys GmbH. The other authors declare no competing interests.

Document is current

Any future updates will be listed below